Makromeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 223,485 | 203,655 | 78,676 | 76,824 | 31,256 | 29,632 | 37,333 | 13,039 |
| Profit before tax | 25,323 | 10,130 | 603 | -4,490 | -20,559 | - | 1,444 | 1,046 |
| Net profit | 23,457 | 8,590 | 603 | -4,490 | -20,559 | -920 | 1,094 | 798 |
| Equity | 22,822 | 31,412 | 22,015 | 17,525 | -3,034 | 6,743 | 7,837 | 8,635 |
| Liabilities | 44,009 | 85,657 | 20,239 | 22,516 | 46,889 | 9,020 | 13,931 | 10,373 |
| Non-current assets | 754 | 871 | 2,128 | 1,760 | 950 | 394 | 0 | 0 |
| Current assets | 66,002 | 116,198 | 40,115 | 38,269 | 42,893 | 15,342 | 21,498 | 18,745 |
| Total assets | 66,756 | 117,069 | 42,243 | 40,029 | 43,843 | 15,736 | 21,498 | 18,745 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 4,651 | 4,534 | 4,946 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +675.3% | -8.9% | -61.4% | -2.4% | -59.3% | -5.2% | +26.0% | -65.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 35.1% | 7.3% | 1.4% | -11.2% | -46.9% | -5.8% | 5.1% | 4.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 102.8% | 27.3% | 2.7% | -25.6% | - | -13.6% | 14.0% | 9.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 10.5% | 4.2% | 0.8% | -5.8% | -65.8% | -3.1% | 2.9% | 6.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 11.3% | 5.0% | 0.8% | -5.8% | -65.8% | - | 3.9% | 8.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.9 | 2.7 | 0.9 | 1.3 | - | 1.3 | 1.8 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 44,697 | 48,877 | 19,669 | 19,206 | 11,721 | 15,460 | 37,333 | 13,039 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Makromeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-11-18 | 2025-11-20 | 2.64 |
| 2024-11-18 | 2024-12-02 | 0.04 |
| 2024-10-29 | 2024-11-06 | 0.04 |
| 2024-10-24 | 2024-10-27 | 0.04 |
| 2024-08-19 | 2024-08-20 | 29.35 |
| 2023-07-24 | 2023-08-09 | 0.14 |
| 2023-04-18 | 2023-04-19 | 157.52 |
| 2022-08-23 | 2022-09-12 | 0.92 |
| 2022-07-25 | 2022-08-11 | 0.92 |
| 2022-04-19 | 2022-05-12 | 109.18 |
Makromeda - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Makromeda, UAB (company code 303084152) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated €13.0K in revenue, down 65.1% year on year and 56.0% over two years, after reaching €37.3K in 2024 and €29.6K in 2023. Despite the weaker turnover in 2025, net profit remained positive at €798, compared with €1.1K in 2024 and a loss of €920 in 2023. The 2025 profit margin was 6.1%, indicating improved profitability on a smaller revenue base. Balance sheet size remained modest, with total assets of €18.7K, equity of €8.6K and liabilities of €10.4K at the end of 2025. The equity ratio stood at 46.1%, debt-to-equity at 1.20, and asset turnover at 0.70x. Return on equity was 9.2% and return on assets 4.3% in 2025. Revenue per employee was €13.0K, and profit per employee was €798.